{"schema_version":"secwatch.filing_event.v1","accession":"0001127537-25-000041","form_type":"8-K","ticker":"LUNG","cik":"0001127537","company_name":"Pulmonx Corp","filed_at":"2025-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.399704+00:00","generated_at":"2026-05-17T22:50:12.509116+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Pulmonx Q2 revenue up 15% to $23.9M but cuts FY2025 guidance to $90-92M","bullets":["Revenue $23.9M (+15% YoY); U.S. $14.7M (+6%), International $9.1M (+32% constant currency +27%).","Net loss $15.2M ($0.38/sh) vs $15.3M ($0.39/sh) prior year; Adjusted EBITDA loss $8.4M vs $7.6M.","Full-year 2025 revenue guidance cut to $90-92M from $96-98M; OpEx lowered to $128-130M from $133-135M.","Gross margin 72% vs 74% prior year; cash, cash equivalents & marketable securities $84.2M.","Added 12 new Zephyr Valve U.S. treatment centers, trained 26 physicians; over 20k first-time patient engagements."],"urls":{"canonical":"https://secwatch.observer/filing/0001127537-25-000041","json":"https://secwatch.observer/filing/0001127537-25-000041.json","markdown":"https://secwatch.observer/filing/0001127537-25-000041.md","text":"https://secwatch.observer/filing/0001127537-25-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1127537/000112753725000041/0001127537-25-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1127537/000112753725000041/lung-20250730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:50:12.509116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}